ABSTRACT Introduction On 31 July 2023, the United States Department of Health and
Human Services announced the formation of the Office of Long COVID Research and …

Alongside vaccines, antiviral drugs are becoming an integral part of our response to the
SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin …

Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …

Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …

A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome
(SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the
spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …